[Entrepreneur] Hong Kong Biotech Start-ups fill the market gap to excel biological drug development. Team with international Biopharm experiences is key to attract overseas businesses opportunity.
Image provided by interviewee
Source: 【初創營商】科企初創搶攻市場缺口 團隊國際化助擴外地
|
Biotechnology start-up build 5 pipelines in 2 years
In addition to Start-ups company from fin-tech and I.T., after the outbreak of the new COVID-19 epidemic, there is more attention paid toward Biotech industry and related therapeutic and diagnostic product. Taron Solutions, based in Hong Kong, is a Contract Development and Manufacturing Organization (CDMO) focus on Biological product development and production. Dr, Alan Chang, CEO and founder of Taron Solutions, point out that a key success to grow a startup company is to understand and position the company according to market demand. Alan said: " In Hong Kong, there are many drug discovery research projects which are potential and demonstrate excellent scientific data and results, yet, a lot of them also fail to move their product forward to the consumer market. Therefore, I found Taron Solutions and take this business opportunities to fill up this market gap and provide solutions to commercialize biological product". " I am glad to see our progress made over the last 2 years, especially when the pandemic hits in 2019. To date, Taron Solutions already has established 5 pipelines, which 4 of these are new biological drug products" Alan added. One of the pipeline is also recognized and funded by the Hong Kong government under ITF and a related business agreement has also established with a Hong Kong listed pharmaceutical company. |
PKU Biologics and Taron Solutions reached a strategic business partnership
agreement
About Peking University Biologics:
Peking University Biologics is a wholly-owned subsidiary of the listed company---Sinobioway Medicine(stock code: 002581). It is currently equipped with many overseas PhD holders which are from well-known pharmaceutical companies in Europe and the United States, such as Pfizer, Novartisch, Sanofi, etc. The company has rich experience in the research and development and production of antibody drugs, recombinant proteins and other macromolecular drugs, and has established a strict quality system and GMP production standards. It aims to help start-up bio-companies by providing research and development to commercial production as well as the approval service of United States, Europe, and Japan.
Peking University Biologics has established R&D technology centers in Shanghai and Hong Kong. Taron Solutions in Hong Kong has a 4000 square foot headquarters and a drug development laboratory, focusing on biological drugs from gene development to CMC services. They have successively completed the pre-clinical research and development of many biomacromolecule drugs and successfully obtained clinical approvals.
Based on China and look to the whole world, Peking University Biologics is accelerating the pace of entering the international biomedicine market, helping global partners to increase the popularity and affordability of biomedicine.
About Taron:
Taron Solutions is the only contract development manufacturing organization, CDMO, that focuses on biologic drugs in Hong Kong from gene development to CMC readiness. Taron chose to focus on biologics because of its higher entry barrier compare to the more common small molecules drug. Biologics productions require manipulations of cells or bacteria to produce the desired drug substance. The whole development and manufacturing process from cell line selection to scale up requires a team with experience and creativity because when manipulating living things, a thorough understanding of the science and a willingness to think outside of the box is necessary.
Furthermore, a drug that seems promising during drug discovery phase might not perform as well in clinical trials if they fail to excel in any parts of CMC regulatory metric. Taron’s management team has the drug development, GMP Production and regulatory experience (US FDA, NMPA, EMA, etc.) to help drug development companies fulfil regulatory requirements and is an invaluable infrastructure for Hong Kong’s budding biotech industry. Taron Solutions complements and enhances the work done by academia and drug development company, by bringing commercial value to their innovation and advancing their drug product to the market.
Within 2 years of operation, Taron Solutions has worked on multiple first in class and biosimilar pipelines for development. Taron Solutions has filed provisional IP for some of the platforms we are building to streamline the drug development cycles and improve the biomanufacturing outcome.
A message from Dr. Alan Chang, CEO and Founder of Taron Solutions:
We are extremely excited with this opportunity to partner with PKU Biologics. Taron’s expertise in international drug regulations, especially with USFDA and the EMA, complements well with PKU’s NMPA expertise. The benefits of our proprietary system design for streamlining early-stage biologics development is also amplified by PKU Biologics impressive manufacturing facility.
Source: PKU Biologics
Peking University Biologics is a wholly-owned subsidiary of the listed company---Sinobioway Medicine(stock code: 002581). It is currently equipped with many overseas PhD holders which are from well-known pharmaceutical companies in Europe and the United States, such as Pfizer, Novartisch, Sanofi, etc. The company has rich experience in the research and development and production of antibody drugs, recombinant proteins and other macromolecular drugs, and has established a strict quality system and GMP production standards. It aims to help start-up bio-companies by providing research and development to commercial production as well as the approval service of United States, Europe, and Japan.
Peking University Biologics has established R&D technology centers in Shanghai and Hong Kong. Taron Solutions in Hong Kong has a 4000 square foot headquarters and a drug development laboratory, focusing on biological drugs from gene development to CMC services. They have successively completed the pre-clinical research and development of many biomacromolecule drugs and successfully obtained clinical approvals.
Based on China and look to the whole world, Peking University Biologics is accelerating the pace of entering the international biomedicine market, helping global partners to increase the popularity and affordability of biomedicine.
About Taron:
Taron Solutions is the only contract development manufacturing organization, CDMO, that focuses on biologic drugs in Hong Kong from gene development to CMC readiness. Taron chose to focus on biologics because of its higher entry barrier compare to the more common small molecules drug. Biologics productions require manipulations of cells or bacteria to produce the desired drug substance. The whole development and manufacturing process from cell line selection to scale up requires a team with experience and creativity because when manipulating living things, a thorough understanding of the science and a willingness to think outside of the box is necessary.
Furthermore, a drug that seems promising during drug discovery phase might not perform as well in clinical trials if they fail to excel in any parts of CMC regulatory metric. Taron’s management team has the drug development, GMP Production and regulatory experience (US FDA, NMPA, EMA, etc.) to help drug development companies fulfil regulatory requirements and is an invaluable infrastructure for Hong Kong’s budding biotech industry. Taron Solutions complements and enhances the work done by academia and drug development company, by bringing commercial value to their innovation and advancing their drug product to the market.
Within 2 years of operation, Taron Solutions has worked on multiple first in class and biosimilar pipelines for development. Taron Solutions has filed provisional IP for some of the platforms we are building to streamline the drug development cycles and improve the biomanufacturing outcome.
A message from Dr. Alan Chang, CEO and Founder of Taron Solutions:
We are extremely excited with this opportunity to partner with PKU Biologics. Taron’s expertise in international drug regulations, especially with USFDA and the EMA, complements well with PKU’s NMPA expertise. The benefits of our proprietary system design for streamlining early-stage biologics development is also amplified by PKU Biologics impressive manufacturing facility.
Source: PKU Biologics
Bringing Biologic Drugs to Market | InvestHK
|
For a drug to be successful, it must undergo vigorous procedures to ensure its efficacy and safety prior to its commercial launch. One that may seem promising during the discovery phase may not perform well in clinical trials if it fails in any part of chemistry, manufacturing and control (CMC) requirements.
Source: https://www.investhk.gov.hk/en/case-studies/bringing-biologic-drugs-market.html |
Taron Solutions is One of The Top 10 Finalist at ATEC’s Startup Competition
Taron Solutions Limited is one of 10 finalist start-up companies chosen from over 80+ international start-ups that participated in Asia Technology Entrepreneurship Conference (ATEC) Startup Competition as a finalist on 09 Nov 19. ATEC is a conference hosted jointly by Harvard, Columbia, Stanford and MIT’s business school and there were many investors present at the competition. The company was the only biotechnology company that was chosen to participate as a finalist, which is a win for not only Taron Solutions, but for the sector in Hong Kong.
CEO of Taron Solutions Alan Chang pitching to the judges at ATEC
For Facebook
-ATEC: https://www.facebook.com/ATECstartup/
-photography by Karen Ma: https://www.facebook.com/owrstudio/
For Instagram
-ATEC: @atecstartup
-photography by Karen Ma: @owr_studio
-ATEC: https://www.facebook.com/ATECstartup/
-photography by Karen Ma: https://www.facebook.com/owrstudio/
For Instagram
-ATEC: @atecstartup
-photography by Karen Ma: @owr_studio
Taron Solutions 4000 sqft Headquarter and Laboratory for Drug Product Development
Taron Solutions recently completed the headquarter office as well as a state-of-the-art laboratory to facilitate the company’s work on several first-in-class drug and biosimilar drug projects. The laboratory contains different equipment for analytical testing, tissue culture, DNA/Protein detection, and cell detection, process development, and cell banking. Taron plans on establishing ISO9001 standard by 2020.
The company’s process development lab will contain bioreactors as well as downstream purification for scale-up optimization.
The company’s process development lab will contain bioreactors as well as downstream purification for scale-up optimization.
|
|
Admittance to Hong Kong Science Park Incubio Program
|
Taron Solutions was successfully admitted into Science Park Incubio program right before Chinese New Year and our move in date for the government subsidized laboratory space is on April 15th.
Taron Solutions are able to carry on some of our advanced R&D and early development service work at this space. Admission in the four year Incubio program include a government grant of HKD 6M paid over the duration of the program. This money can be used towards our Science Park rent and for hiring PhDs. |
Our pilot facility handles early stage bioprocess development up to Phase 2 GMP clinical production
Pilot Facility (Under Construction)
- Size of facility: Approximately 14,000 sq. ft
- Production Scale: Up to 500 L (x 2) with potential to expand
- Our facility handles cell banking, early stage bioprocess development, up to Phase 2 GMP clinical production
- In-house supporting functions such as QC testing labs, GMP warehouse, bio-waste and waste water treatment, utilities (e.g., HVAC, WFI, Clean Steam etc.), process automation systems
- Commencement for GMP manufacturing is ~2 years from the start of facility renovation